{"entity":{"id":"nct07519772","kind":"trial","name":"A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","aka":[],"tldr":"A phase 1/2 trial of MK-1045 in non-hodgkin lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) is a phase 1/2 interventional study registered as NCT07519772 by Merck Sharp & Dohme LLC, with 280 participants planned, started 2026-05-03 and due to reach its primary completion in 2030-07-01. Interventions recorded: MK-1045. Conditions listed: Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07519772","url":"https://clinicaltrials.gov/study/NCT07519772"}],"tags":["ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["mk-1045"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07519772","phase":"1/2","setting":"A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma","sponsor":"Merck Sharp & Dohme LLC","enrolled":280,"outcomes":[]},"route":"/trials/nct07519772/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"mk-1045","kind":"drug","name":"MK-1045","route":"/drugs/mk-1045/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}